These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26808355)

  • 1. Role of Bismuth in the Eradication of Helicobacter pylori.
    Alkim H; Koksal AR; Boga S; Sen I; Alkim C
    Am J Ther; 2017; 24(6):e751-e757. PubMed ID: 26808355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of
    Suzuki S; Esaki M; Kusano C; Ikehara H; Gotoda T
    World J Gastroenterol; 2019 Apr; 25(16):1907-1912. PubMed ID: 31086459
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of second-line regimens for
    Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
    Basyigit S; Kefeli A; Sapmaz F; Yeniova AO; Asilturk Z; Hokkaomeroglu M; Uzman M; Nazligul Y
    Bosn J Basic Med Sci; 2015 Oct; 15(4):50-4. PubMed ID: 26614852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 6. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
    Fallone CA; Moss SF; Malfertheiner P
    Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori eradication therapy.
    Suzuki H; Nishizawa T; Hibi T
    Future Microbiol; 2010 Apr; 5(4):639-48. PubMed ID: 20353303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
    Tefera S; Berstad A; Bang CJ; Nysaeter G; Hatlebakk JG; Olafsson S; Nesje LB; Hausken T; Berstad K; Hundal O
    Am J Gastroenterol; 1996 May; 91(5):935-41. PubMed ID: 8633584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis.
    Ko SW; Kim YJ; Chung WC; Lee SJ
    Helicobacter; 2019 Apr; 24(2):e12565. PubMed ID: 30698318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line bismuth-containing quadruple therapy for
    Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD
    World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
    van der Wouden EJ; Thijs JC; van Zwet AA; Kooy A; Kleibeuker JH
    Am J Gastroenterol; 1998 Aug; 93(8):1228-31. PubMed ID: 9707042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.
    Graham DY; Lee SY
    Gastroenterol Clin North Am; 2015 Sep; 44(3):537-63. PubMed ID: 26314667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Helicobacter pylori - 2012].
    Buzás GM
    Orv Hetil; 2012 Sep; 153(36):1407-18. PubMed ID: 22951408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
    Chey WD; Leontiadis GI; Howden CW; Moss SF
    Am J Gastroenterol; 2017 Feb; 112(2):212-239. PubMed ID: 28071659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
    Zhou L; Zhang J; Song Z; He L; Li Y; Qian J; Bai P; Xue Y; Wang Y; Lin S
    Helicobacter; 2016 Apr; 21(2):91-9. PubMed ID: 26104022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.